Phio Pharmaceuticals Corp.
NASDAQ: PHIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert L. Bitterman
- Employees
- 6
- Headquarters
- Marlborough, United States
- IPO year
- 2012
- Market cap
- $11.8M
- Website
- https://www.phiopharma.com
Loading PHIO…
Loading profile data…Frequently asked questions about PHIO
What does Phio Pharmaceuticals Corp. (PHIO) do?
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specif...
Where does PHIO trade?
Phio Pharmaceuticals Corp. (PHIO) trades on the NASDAQ.
What sector is PHIO in?
Phio Pharmaceuticals Corp. (PHIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Phio Pharmaceuticals Corp.?
Robert L. Bitterman is the chief executive officer of Phio Pharmaceuticals Corp. (PHIO).
Where is Phio Pharmaceuticals Corp. headquartered?
Phio Pharmaceuticals Corp. is headquartered in United States.
Does PHIO pay a dividend?
Phio Pharmaceuticals Corp. (PHIO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PHIO go public?
Phio Pharmaceuticals Corp. (PHIO) completed its initial public offering in 2012.